Received Apr 10, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | Y012921 | OT |
no additional AE; Administration of a "GARDASIL" that had experienced a temperature excursion; This spontaneous report was received from other health professional, concerning a 13-year-old female patient. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On 08-Oct-2025, a temperature excursion (TE) occurred for 1000 time (units not provided), minimum temperature -2° and maximum 8.59, when discovered (17-Oct-2025) 3.55° for Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9). On 16-Oct-2025, the patient was vaccinated with a vaccine involved in the TE, as the first dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) (lot #Y012921 has been verified to be valid, expiration date reported and confirmed as 08-Jan-2027), , administered by Intramuscular route, as prophylaxis. (Product storage error). No additional adverse event reported (No adverse event). This is one of several reports received from the same reporter.